Clinical research company Nucleus Network revealed that, it would test the effectiveness and safety of a Recombinant Spike Protein Nanoparticle vaccine, NVX-CoV2373, developed by US based Biotechnology Company.

A small group of healthy volunteers would be recruited for the trial to test the effectiveness of this vaccine. The human trial procedures would involve four phases, following strict protocols to make sure it was safe and effective before being released to the public.